Advertisement

Child's Nervous System

, Volume 35, Issue 1, pp 47–52 | Cite as

Peripheral nerve injuries in the pediatric population: a review of the literature. Part III: peripheral nerve tumors in children

  • Javier Robla Costales
  • Mariano SocolovskyEmail author
  • Jaime A. Sánchez Lázaro
  • Rubén Álvarez García
  • David Robla Costales
Review Paper

Abstract

Introduction

Peripheral nerve tumors type, inciedence and treatment in the pediatric population should be analyzed.

Methods

We have performed an extense literature review of this subject.

Results

incidence and distribution are similar to those observed in adults. The most common peripheral nerve tumors in children are neurofibromas and schwannomas. Malignant peripheral nerve sheath tumors are also observed, specially associated with genetic syndromes, like neurofibromatosis and Carney complex.

Conclusion

In this review, peripheral nerve tumors have been divided into three categories to aid with understanding: reactive and hyperplastic lesions, benign tumors, and malignant tumors. The most frequent lesions have been described.

Keywords

Peripheral nerve tumors Pediatric population Neurofibromas Schwannomas 

Introduction

Most peripheral nerve tumors observed in adults can also be found in children. The most frequently observed peripheral nerve tumors in children are neurofibromas, schwannomas, and malignant peripheral nerve sheath tumors (MPNSTs), with neurofibromas and schwannomas accounting for the vast majority of pediatric peripheral nerve tumors [1]. Although some of these tumors occur in isolation, they also may be seen in the context of tumor syndromes, like neurofibromatosis and Carney complex. In this review, peripheral nerve tumors have been divided into three categories to aid with understanding: benign tumors, malignant tumors, and reactive and hyperplastic lesions.

Benign tumors

Neurofibromas

Neurofibromas are the most common type of benign peripheral nerve tumor [2]. They are of Schwann cells lineage and have either a well-demarcated intraneural or diffuse infiltrative growth pattern [3]. These tumors are composed of the constitutive elements of a normal nerve (Schwann cells and fibroblasts) in addition to perineural-like cells, intercalated with nerve fibers, and embedded in a myxoid matrix. Single or multiple nerve fascicles that enter and leave the tumor can be identified. Axons present within the tumor comprise an important feature that distinguishes neurofibromas from schwannomas [4].

Although many neurofibromas are associated with neurofibromatosis type 1 (NF-1), a sizeable proportion of neurofibromas occur sporadically.

Four classifications of neurofibroma are recognized and defined according to their architectural growth patterns, all of which can be seen in children. They are localized, diffuse, plexiform, and massive soft-tissue neurofibromas [3]. The most common are localized cutaneous neurofibromas; small nodular masses that arise from a small cutaneous nerve. Localized intraneural neurofibromas are deeper focal lesions that may involve major peripheral nerves or a plexus, and typically result in fusiform expansion of the nerve trunk. Plaque-like enlargement of a nerve, usually in the head and neck region, characterizes diffuse neurofibromas [4]. Localized and diffuse neurofibromas tend to occur sporadically and are not related to NF-1. Together, these two forms comprise 90% of neurofibromas [1]. Diffuse neurofibromas preferentially affect children [5].

Plexiform neurofibromas are multinodular, tortuous, and elongated masses characterized by the involvement of multiple adjacent nerve fascicles or components of a plexus. Their appearance has been described as resembling a “bag of worms” [6]. This subtype is rarely seen as a sporadic lesion; it is almost always associated with NF-1. Plexiform neurofibromas have the potential for malignant transformation. Massive soft tissue neurofibromas represent a very rare subtype, which is characterized by extensive, diffuse infiltration of soft tissue and skeletal muscle, usually causing regional or single-limb enlargement. This subtype is also almost always associated with NF-1.

Schwannomas

Schwannomas are the second most common type of peripheral nerve tumor in children. The majority occur sporadically. They are typically a well circumscribed, encapsulated mass of neoplastic Schwann cell origin [3]. These tumors arise from a single nerve root or peripheral nerve fascicle and grow in an eccentric fashion, progressively displacing uninvolved fascicles [4]. The classical histological architecture of a schwannoma is biphasic with dense compact areas called Antoni A and less-compact areas called Antoni B. Some of the cells may palisade to form Verocay bodies within the Antoni A areas [1].

As stated earlier, in most patients, schwannomas occur sporadically as solitary masses. However, they are also seen as one component of complex disorders, like NF-2, schwannomatosis, Carney complex, and a dominant syndrome associated with multiple schwannomas, multiple nevi, and multiple vaginal leiomyomas [7, 8]. Schwannomas are not associated with NF-1.

Many authors consider schwannomatosis to be a third form of neurofibromatosis. It is characterized by the presence of multiple schwannomas in the absence of the vestibular schwannomas required for a diagnosis of NF-2 [1].

There are other pathological variants of schwannoma, including plexiform, melanotic, and cellular forms. The melanotic subtype is rare, characterized by the marked accumulation of melanin in neoplastic cells and associated melanophages. Unlike other schwannomas, this subtype can become malignant and is associated with Carney complex; in fact, psammomatous melanotic schwannomas are listed as one of the major diagnostic criteria for Carney complex [9].

Perineuriomas

Perineuriomas are uncommon benign tumors composed of differentiated perineurial cells. These tumors stem from cells located in the perineurium of the peripheral nerve, where they form a blood-nerve barrier. They can mimic certain benign and malignant soft-tissue lesions [10], so immunohistochemical and/or ultrastructural confirmation of perineurial cell differentiation is necessary for the diagnosis.

These tumors can be classified into two main types: intraneural perineuromas and extraneural soft tissue perineuromas [4].

Intraneural perineuriomas most often affect patients in the second or third decade of life and appear as fusiform masses along the path of a large nerve (e.g., as localized cylindrical enlargement over a few centimeters) [10]. Affected patients typically present with a slowly progressive, painless swelling of a peripheral nerve associated with gradual loss of motor and sensory function [1]. Progressive muscle weakness, with or without atrophy, is markedly more common than pain or sensory disturbances [11].

Extraneural soft tissue perineuriomas are more frequent than their intraneural counterparts, usually asymptomatic, and tend to occur in middle-aged adults.

Perineuriomas have been reported in children [11, 12, 13, 14]. Although, as stated above, most intraneural perineuromas are diagnosed in the second or third decade of life, roughly half of reported patients with a perineurioma started having symptoms prior to adulthood. The diagnosis is generally established late, however, because there is typically no pain and many children remain unaware of the progressive functional impairment that is occurring [11].

Fascicular biopsy may be indicated for a definitive diagnosis; however, in most patients, the clinical pattern, together with the tumor’s radiological and surgical appearance, allows clinicians to make the diagnosis without histological confirmation [11, 15].

With respect to treatment, some have advocated resecting and grafting focal lesions; however, tumor resection and nerve reconstruction has proved to be of no benefit, and tendon transfers can be considered for the majority of patients [11, 15].

In any child with a motor deficit involving a single major nerve or plexus as the only meaningful symptom, the possibility of a perineurioma should be entertained during diagnostic workup [11].

Neurothekeomas

Neurothekeomas and nerve sheath myxomas used to be designated as the same tumor. Both are superficial slow-growing tumors that usually are asymptomatic [16]. Contrary to nerve sheath myxomas, however, cellular neurothekeomas have negative S100 staining, which indicates they are not of Schwann cell origin [17]. Also, contrary to nerve sheath myxomas, neurothekeomas have a predilection for the upper limbs, head, and neck of pediatric and young adult females [18, 19, 20].

Nerve sheath myxomas

As just stated, nerve sheath myxomas and neurothekeomas are similar entities that once were mistakenly classified as the same tumor. Now, nerve sheath myxomas are considered to be significantly rarer than neurothekeomas, such that, unlike neurothekeomas, they no longer are deemed to be a significant tumor type within the pediatric population [1].

Ganglioneuromas

Ganglioneuromas are rare tumors that arise from sympathetic ganglion cells. They are large, slow-growing, encapsulated tumors that histologically consist of mature ganglion cells (neurons), axons, satellite cells, Schwann cells, and fibrous stroma [21]. They are considered the benign counterpart of ganglioneuroblastomas and neuroblastomas. The absence of immature elements distinguishes ganglioneuromas from these latter two entities [1].

More frequent in young females, such masses can occur anywhere along the sympathetic nerve chain, though the mediastinum, retroperitoneum, and adrenal glands are common locations [22]. Although usually asymptomatic, they can be associated with specific complaints due to their local mass effect. Malignant transformation has been reported [4].

Ganglioneuromas have been reported in children [23, 24, 25].

Malignant peripheral nerve tumors

Malignant tumors affecting peripheral nerves remain a challenge, both diagnostically and therapeutically, and the mechanisms responsible for their development are still incompletely understood. Malignant peripheral nerve tumors can be classified into neurogenic tumors (i.e., malignant peripheral nerve sheath tumors) and non-neurogenic tumors (synovial sarcomas, Pancoast tumors, soft tissues sarcomas, lymphomas, and intraneural metastases) [15]. Non-neurogenic tumors have been reported in adults, but not in children.

Malignant peripheral nerve sheath tumor (MPNST)

Malignant peripheral nerve sheath tumors (MPNST) account for all malignant tumors arising from the nerve sheath of the peripheral nerves. These tumors can arise from any peripheral nerve, but larger nerve trunks—including the brachial plexus, sacral plexus, and sciatic nerve—are the most common sites [26]. They are aggressive soft tissue sarcomas that account for 5–10% of soft tissue sarcomas [27].

A sarcoma is considered an MPNST if it arises within or from a peripheral nerve, or alternatively arises from a pre-existing benign or other malignant nerve sheath tumor. It is also considered an MPNST if it has the appearance of an MPNST in a patient with NF-1 or if it has the appearance of an MPNST and histologic, immunohistochemical, or ultrastructural features suggestive of Schwann cell differentiation [15].

On gross anatomical study, MPNSTs appear whitish-tan to yellow on cut surface and may exhibit necrosis and hemorrhage. Histologic characteristics of these tumors include high cellularity, nuclear atypia, mitotically active spindle cells, abrupt variation in cellularity, and increased perivascular cellularity. Mitotic figures are visualized in more than four per ten high-power fields [1]. Distinction from other sarcomatous lesions is sometimes challenging.

These tumors have no gender or racial associations and tend to occur in patients between the ages of 20 and 50 years. The main risk factor for developing an MPNST is the presence of NF-1, with NF-1 patients accounting for more than half of all MPNSTs [15]. The reported lifetime risk of an individual with NF-1 developing MPNST generally ranges between 2 and 10% [1], with patients having internal plexiform neurofibromas at even greater risk (10–15% of patients’ progress to MPNST). NF-1 patients generally develop their MPNST at a slightly younger age than the general population, but the majority of cases still present in adulthood [1, 15]. Most sporadic and all NF-1-associated MPNSTs carry the NF-1 deletion, but the malignant transformation process is still not well understood [1].

Radiation exposure, the other important risk factor for developing an MPNST, is associated with approximately 10% of MPNSTs. On average, radiation-related MPNSTs occur 15 years after radiation exposure (range 4 to 41 years) [15].

In one series, regional lymph node involvement was observed in 9% of patients and distant metastases in 6% [28], but, in another series, a much higher incidence of regional lymph node involvement (31.7%) was evident [26].

Patients usually present with a growing mass and neurological manifestations attributable to the involved neural structure. Magnetic resonance imaging has little value in terms of distinguishing MPNSTs from schwannomas. Positron emission tomography (PET) has been advocated as an adjunct study to identify increased metabolic activity [1].

Gross total resection with wide margins is the preferred primary treatment of MPNSTs and has been shown to be the strongest predictor of overall survival. Sometimes, however, gross total resection is either impossible or associated with significant functional loss due to the resection of adjacent major vessels and/or nerves. Other prognostic indicators are tumor size and the coexistence of neurofibromatosis [26, 29].

Radiation therapy has been used as an adjuvant treatment in cases of MPNST that could not be fully resected to improve local control of the disease. These tumors are usually considered to exhibit uncertain chemosensitivity, but recent evidence suggests that there may be a role for chemotherapy in patients with high-grade histology [26, 29, 30, 31].

Roughly 10–20% of patients with MPNSTs present during childhood [32, 33]. In 2014, Bates et al. published their analysis of data on pediatric MPNST patients extracted from the SEER-18 database, a database that provides information on the US population from 1973 to 2009. They identified 165 pediatric-age MPNST patients, ranging in age from infancy to 19 years old. After exclusions, 139 patients in the SEER-18 database met study criteria for outcomes analysis. The overall incidence of MPNST in children under 19 years old was found to be 0.56 per million person-years. No gender or racial associations were observed. Among children, those in their first year of life, those between 1 and 4 years old and those between 5 and 9 years old all exhibited a statistically lower incidence of MPNST than adolescents between the ages of 15 and 19. Median overall survival in the pediatric population was 30 months. On multivariate analysis, only localized disease and treatment with surgery were positive prognostic factors [26]. In another study, among 167 pediatric patients with MPNST, overall 5-year survival was 43–59%, while 5-year progression-free survival was 29–45% [28].

Three cases of MPNST have been reported in children, all 6 to 13 years old, who presented with a primary bone neoplasm in the absence of NF-1 [34].

Reactive and hyperplastic lesions

Neuromas

The most frequent type of pediatric neuroma is a traumatic neuroma that results from a peripheral nerve injury. Other neuromas—like Morton’s neuromas, Pacinian neuromas, and palisaded-encapsulated neuromas are extremely rare in this age group.

Morton’s neuromas are very infrequent in patients younger than 20 years old [1, 35]. Palisaded-encapsulated neuromas, a non-traumatic type of neuroma, can present in children, though they tend to present in the fifth to seven decades of life [36, 37, 38]. Neuromas also can be associated with a variety of syndromes, including multiple mucosal neuroma syndrome and multiple endocrine neoplasia syndrome (MEN 2B). A congenital Pacinian neuroma has been reported [39].

Intraneural ganglion cysts

Intraneural ganglion cysts are non-neoplastic, fluid-filled cystic formations contained within the epineurium of the peripheral nerves. Although many peripheral nerves may be affected, the common peroneal nerve, at the fibular neck, is by far the most frequently affected site [40, 41, 42]. This condition is a rare clinical entity in adults, but even rarer in children, with fewer than 70 cases reported in published literature [41, 43, 44].

The pathogenesis of intraneural ganglion cysts remained controversial until Spinner proposed a unifying articular theory [40, 45]. According to Spinner, the formation of intraneural ganglion cysts in a peroneal nerve is a dynamic process that typically starts in a degenerating superior tibiofibular joint and subsequently extends to the nerve along its articular branch in the intra-epineural space via the path of least resistance as determined by pressure fluxes [42]. Surgical management consists of disconnecting the articular branch of the peroneal nerve and decompression, rather than resection, of the cyst.

Excellent surgical results and a favorable prognosis have recently been reported in children, much better than the outcomes typically achieved in adults [41].

Lipomatous tumors

Lipomatous tumors consist of adipose tissue, which either may be encapsulated or infiltrate adjacent neural structures [1]. The spectrum of adipose lesions of nerves is broad, including extra/intraneural lipomas, neural lipomatosis, and various combinations of these two lesions. Lipomatous tumors involving nerves are rare, but have been reported in children [46].

Biopsy is not necessary for the diagnosis of lipomatous tumors because of their pathognomonic appearance on magnetic resonance imaging (MRI). Intraneural lipomas can be resected safely, since they are focal deposits of fat that displace fascicles. However, lipomatosis of major nerves should not be resected because it is a more diffuse process in which fat is inter-dispersed between fascicles [15]. Decompression of the enlarged nerve may be indicated in some cases of lipomatosis.

Neuromuscular choristomas

Neuromuscular choristomas are benign lesions defined by the presence of mature striated muscle within the normal epineurium of a peripheral nerve [1]. These lesions are extremely rare, with only one case reported in a child [47].

Hansen’s disease

Hansen’s disease, historically called leprosy, can affect children who have lived in or traveled to endemic areas and may cause the tumor-like expansion of peripheral nerves. It is a common chronic infectious condition in the Third World, where it is the most frequently encountered treatable cause of peripheral neuropathy [48]. Hansen’s disease usually presents with dermatologic manifestations and lost sensation in the distribution of affected nerves. Peripheral nerves are always involved and sensory disturbances are the most common clinical manifestation of this condition [48]. The ulnar nerve is the nerve most frequently affected.

In the rare case of pure neuritic leprosy, leprosy may be difficult to distinguish from a true tumor without biopsy. Pathological examination reveals a grossly thickened nerve. Microscopic examination reveals a destructive, inflammatory granulomatous process in the nerve with intense lymphocytic infiltration [48]. Some fascicles may be totally destroyed, while others appear almost normal. Fite’s acid fast stain can be used to visualize the offending mycobacteria and confirm the diagnosis; polymerase chain reaction (PCR) testing also is available [49].

With appropriate treatment, nerve inflammation can abate and further neurological impairment may be halted. Existing neurologic deficits will persist, however [1]. Surgical procedures mostly include tendon transfers. Improved sensory function has been reported in some patients following nerve grafts [50].

Conclusions

Peripheral nerve tumors are much the same in children and adolescents as in adults. The most common peripheral nerve tumors in children are neurofibromas and schwannomas. Malignant peripheral nerve sheath tumors are another significant subset of tumors, particularly in the setting of tumor syndromes, especially NF-1. The other lesions described in this review are mostly exceedingly rare and their presentations anecdotal.

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interests.

References

  1. 1.
    Baccon J, Wellons JC, Rizk EB (2015) Pediatric peripheral nerve tumors. In: Tubbs RS, Rizk E, Shoja M, Loukas M, Barbaro N, Spinner E (eds) Nerves and nerve injuries. Vol 2: Pain, treatment, injury, disease and future directions. Academic press, London, pp 839–846Google Scholar
  2. 2.
    Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG (2005) A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 102:246–255CrossRefGoogle Scholar
  3. 3.
    Rodriguez FJ, Folpe AL, Giannini C, Perry A (2012) Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol (Berl) 123:295–319CrossRefGoogle Scholar
  4. 4.
    Guedes-Corrêa JF, Torrao FJL, Barbosa D (2017) Benign peripheral nerve tumors. In: manual of peripheral nerve surgery: from the basics to complex procedures. Thieme Medical Publishers, Stuttgart, pp 184–194Google Scholar
  5. 5.
    Hassell DS, Bancroft LW, Kransdorf MJ, Peterson JJ, Berquist TH, Murphey MD, Fanburg-Smith JC (2008) Imaging appearance of diffuse neurofibroma. AJR Am J Roentgenol 190:582–588CrossRefGoogle Scholar
  6. 6.
    Gabhane SK, Kotwal MN, Bobhate SK (2009) Morphological spectrum of peripheral nerve sheath tumors: a series of 126 cases. Indian J Pathol Microbiol 52:29–33CrossRefGoogle Scholar
  7. 7.
    Evans DGR (2009) Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med Off J Am Coll Med Genet 11:599–610Google Scholar
  8. 8.
    MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES (2005) Diagnostic criteria for schwannomatosis. Neurology 64:1838–1845CrossRefGoogle Scholar
  9. 9.
    Rodriguez FJ, Stratakis CA, Evans DG (2012) Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. Acta Neuropathol (Berl) 123:349–367CrossRefGoogle Scholar
  10. 10.
    Rankine AJ, Filion PR, Platten MA, Spagnolo DV (2004) Perineurioma: a clinicopathological study of eight cases. Pathology (Phila) 36:309–315Google Scholar
  11. 11.
    Ferraresi S, Garozzo D, Bianchini E, Gasparotti R (2010) Perineurioma of the sciatic nerve: a possible cause of idiopathic foot drop in children: report of 4 cases. J Neurosurg Pediatr 6:506–510CrossRefGoogle Scholar
  12. 12.
    Roux A, Tréguier C, Bruneau B, Marin F, Riffaud L, Violas P, Michel A, Gandon Y, Gauvrit JY (2012) Localized hypertrophic neuropathy of the sciatic nerve in children: MRI findings. Pediatr Radiol 42:952–958CrossRefGoogle Scholar
  13. 13.
    Ridel P, Perrot P, Moreau A, Duteille F (2014) A rare tumor of the median nerve in a young child: intraneural perineurioma. About one clinical case. Ann Chir Plast Esthet 59:204–207CrossRefGoogle Scholar
  14. 14.
    Al-Adnani M (2017) Soft tissue perineurioma in a child with neurofibromatosis type 1: a case report and review of the literature. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 20:444–448CrossRefGoogle Scholar
  15. 15.
    Spinner RJ, Hébert-Blouin M, Zager EL (2011) Peripheral nerve tumors. In: Siqueira M, Socolovsky M, Malessy M, Devy I (eds) treatment of peripheral nerve lesions. Prism Publications, Bangalore, pp 155–170Google Scholar
  16. 16.
    Fetsch JF, Laskin WB, Hallman JR, Lupton GP, Miettinen M (2007) Neurothekeoma: an analysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am J Surg Pathol 31:1103–1114CrossRefGoogle Scholar
  17. 17.
    Rasulic L, Samardzic M, Bascarevic V, Micovic M, Cvrkota I, Zivkovic B (2015) A rare case of peripheral nerve hemangioblastoma—case report and literature review. Neurosurg Rev 38:205–209 discussion 209CrossRefGoogle Scholar
  18. 18.
    Hornick JL, Fletcher CDM (2007) Cellular neurothekeoma: detailed characterization in a series of 133 cases. Am J Surg Pathol 31:329–340CrossRefGoogle Scholar
  19. 19.
    Ahmed I, Rawat JD, Singh S et al (2010) Neurothekeoma: a rare sacrococcygeal tumor in a child. J Pediatr Surg 45:1037–1039CrossRefGoogle Scholar
  20. 20.
    Seo BF, Kang H, Lee JY et al (2013) Ankle neurothekeoma: a case report. J Foot Ankle Surg Off Publ Am Coll Foot Ankle Surg 52:678–680Google Scholar
  21. 21.
    Skovronsky DM (2004) Pathologic classification of peripheral nerve tumors. Neurosurg Clin N Am 15(2):157–166CrossRefGoogle Scholar
  22. 22.
    Modha A (2005) Presacral ganglioneuromas. Report of five cases and review of the literature. J Neurosurg Spine 2(3):366–371CrossRefGoogle Scholar
  23. 23.
    Albuquerque BS (2013) Surgical management of parapharyngeal ganglioneuroma: case report and review of the literature. ORL J Otorhinolaryngol Relat Spec 75(4):240–244CrossRefGoogle Scholar
  24. 24.
    Matthews MA (2013) Diffuse intestinal ganglioneuromatosis in a child. J Pediatr Surg 48(5):1129–1133CrossRefGoogle Scholar
  25. 25.
    Scheithauer BW (2008) Diffuse ganglioneuromatosis and plexiform neurofibroma of the urinary bladder: report of a pediatric example and literature review. Hum Pathol 39(11):1708–1712CrossRefGoogle Scholar
  26. 26.
    Bates JE, Peterson CR, Dhakal S, Giampoli EJ, Constine LS (2014) Malignant peripheral nerve sheath tumors (MPNST): a SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population. Pediatr Blood Cancer 61:1955–1960CrossRefGoogle Scholar
  27. 27.
    Stark AM, Buhl R, Hugo HH, Mehdorn HM (2001) Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir 143(4):357–363 discussion 363–4CrossRefGoogle Scholar
  28. 28.
    Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, de Sio L, Koscielniak E, Sotti G, Treuner J (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol Off J Am Soc Clin Oncol 23:8422–8430CrossRefGoogle Scholar
  29. 29.
    Yohay K (2009) Neurofibromatosis type 1 and associated malignancies. Curr Neurol Neurosci Rep 9:247–253CrossRefGoogle Scholar
  30. 30.
    Ferrari A, Bisogno G, Carli M (2007) Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs 9:239–248CrossRefGoogle Scholar
  31. 31.
    Karpinsky G, Krawczyk MA, Izycka-Swieszewska E, Fatyga A, Budka A, Balwierz W, Sobol G, Zalewska-Szewczyk B, Rychlowska-Pruszynska M, Klepacka T, Dembowska-Baginska B, Kazanowska B, Gabrych A, Bien E (2018) Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol 144:519–529CrossRefGoogle Scholar
  32. 32.
    Amirian ES, Goodman JC, New P, Scheurer ME (2014) Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neuro-Oncol 116:609–616CrossRefGoogle Scholar
  33. 33.
    Casanova M, Ferrari A, Spreafico F, Luksch R, Terenziani M, Cefalo G, Massimino M, Gandola L, Lombardi F, Fossati-Bellani F (1999) Malignant peripheral nerve sheath tumors in children: a single-institution twenty-year experience. J Pediatr Hematol Oncol 21:509–513CrossRefGoogle Scholar
  34. 34.
    Wesche WA, Khare V, Rao BN et al (1999) Malignant peripheral nerve sheath tumor of bone in children and adolescents. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 2:159–167CrossRefGoogle Scholar
  35. 35.
    Kasparek M, Schneider W (2013) Surgical treatment of Morton’s neuroma: clinical results after open excision. Int Orthop 37(9):1857–1861CrossRefGoogle Scholar
  36. 36.
    Omori Y, Tanito K, Ito K, Itoh M, Saeki H, Nakagawa H (2014) A pediatric case of multiple palisaded encapsulated neuromas of the palms and soles. Pediatr Dermatol 31:e107–e109CrossRefGoogle Scholar
  37. 37.
    Moore RL, White CR (2010) Multiple palisaded encapsulated neuromas in a child without other associated abnormalities. J Am Acad Dermatol 62:358–359CrossRefGoogle Scholar
  38. 38.
    Hall LD, Ferringer T (2013) Palisaded encapsulated neuroma. Cutis 92(167):177–178Google Scholar
  39. 39.
    Altmeyer P (1979) Histology of a plexiform neuroma with Vater-Pacini-lamellar-corpuscle-like structures. Hautarzt Z Dermatol Venerol Verwandte Geb 30:248–252Google Scholar
  40. 40.
    Spinner RJ, Scheithauer BW, Amrami KK (2009) The unifying articular (synovial) origin of intraneural ganglia: evolution-revelation-revolution. Neurosurgery 65(4 Suppl):A115–A124CrossRefGoogle Scholar
  41. 41.
    Robla-Costales J, Socolovsky M, Dubrovsky A et al (2011) Intraneural cysts of the peroneal nerve in childhood: report of 2 cases and literature review. Neurocir Astur Spain 22:324–331CrossRefGoogle Scholar
  42. 42.
    Consales A, Pacetti M, Imperato A, Valle M, Cama A (2016) Intraneural ganglia of the common peroneal nerve in children: case report and review of the literature. World Neurosurg 86:510.e11–510.e17CrossRefGoogle Scholar
  43. 43.
    Nucci F, Artico M, Santoro A, Bardella L, Delfini R, Bosco S, Palma L (1990) Intraneural synovial cyst of the peroneal nerve: report of two cases and review of the literature. Neurosurgery 26:339–344CrossRefGoogle Scholar
  44. 44.
    Desy NM, Spinner RJ (2016) Pediatric intraneural ganglia: the value of a systematic review for “orphan” conditions. World Neurosurg 91:658–659.e2CrossRefGoogle Scholar
  45. 45.
    Spinner RJ et al (2003) Peroneal intraneural ganglia: the importance of the articular branch. Clinical series. J Neurosurg 99(2):319–329CrossRefGoogle Scholar
  46. 46.
    Spinner RJ, Scheithauer BW, Amrami KK, Wenger DE, Hébert-Blouin MN (2012) Adipose lesions of nerve: the need for a modified classification. J Neurosurg 116:418–431CrossRefGoogle Scholar
  47. 47.
    Maher CO, Spinner RJ, Giannini C, Scheithauer BW, Crum BA (2002) Neuromuscular choristoma of the sciatic nerve. Case report. J Neurosurg 96:1123–1126CrossRefGoogle Scholar
  48. 48.
    Ouvrier RA, McLeod JG, Pollard JD (1999) Peripheral neuropathy in childhood, 2nd edn. MacKeith Press, LondonGoogle Scholar
  49. 49.
    Moschella SL (2004) An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 51:417–426CrossRefGoogle Scholar
  50. 50.
    McLeod JG, Hargrave JC, Gye RS et al (1975) Nerve grafting in leprosy. Brain J Neurol 98:203–212CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Universidad de LeónLeónSpain
  2. 2.Peripheral Nerve & Brachial Plexus Surgery Program, Department of NeurosurgeryUniversity of Buenos Aires School of MedicineBuenos AiresArgentina
  3. 3.Department of Plastic SurgeryComplejo Asistencial Universitario de LeónLeónSpain

Personalised recommendations